Literature DB >> 25883199

Lag-censoring analysis: lights and shades.

Giovanni Tripepi1, Georg Heinze2, Kitty J Jager3, Vianda S Stel3, Friedo W Dekker4, Carmine Zoccali1.   

Abstract

'Intention-to-treat' (ITT) analysis is the recommended approach for the data analysis of randomized clinical trials (RCT). ITT analysis considers patients in the active or in the control arm as originally allocated by randomization, independently of their actual adherence to the assigned treatment. Lag-censoring analysis is a statistical method which takes into account the compliance of patients to the study protocol because the investigator censors a patient when or shortly after he/she stops the treatment being tested. Herein we describe the methodology underlying lag-censoring analysis in general terms and by considering the application of this technique in the analysis of a large RCT in haemodialysis patients, the Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events (EVOLVE) trial. Use and misuse of this technique are discussed.
© The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  intention-to-treat analysis; lag-censoring analysis

Mesh:

Year:  2015        PMID: 25883199     DOI: 10.1093/ndt/gfv068

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  2 in total

1.  A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet.

Authors:  Björn Stollenwerk; Sergio Iannazzo; Ron Akehurst; Michael Adena; Andrew Briggs; Bastian Dehmel; Patrick Parfrey; Vasily Belozeroff
Journal:  Pharmacoeconomics       Date:  2018-05       Impact factor: 4.981

Review 2.  Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis.

Authors:  Patrick S Parfrey; Geoffrey A Block; Ricardo Correa-Rotter; Tilman B Drüeke; Jürgen Floege; Charles A Herzog; Gerard M London; Kenneth W Mahaffey; Sharon M Moe; David C Wheeler; Glenn M Chertow
Journal:  Clin J Am Soc Nephrol       Date:  2015-11-27       Impact factor: 8.237

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.